Nektar Therapeutics (NKTR) Given a $47.00 Price Target by HC Wainwright Analysts

HC Wainwright set a $47.00 price objective on Nektar Therapeutics (NASDAQ:NKTR) in a research report sent to investors on Monday morning. The brokerage currently has a hold rating on the biopharmaceutical company’s stock.

Several other research analysts have also recently weighed in on NKTR. TheStreet cut shares of Nektar Therapeutics from a c rating to a d+ rating in a report on Wednesday, November 7th. Cowen reissued a buy rating and set a $86.00 price objective on shares of Nektar Therapeutics in a report on Thursday, November 8th. Zacks Investment Research raised shares of Nektar Therapeutics from a hold rating to a buy rating and set a $54.00 price objective for the company in a report on Monday, July 16th. Jefferies Financial Group decreased their price objective on shares of Nektar Therapeutics from $103.00 to $73.00 and set a buy rating for the company in a report on Thursday, November 8th. Finally, BidaskClub cut shares of Nektar Therapeutics from a hold rating to a sell rating in a report on Wednesday, October 24th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company’s stock. The company has an average rating of Hold and an average target price of $85.78.

Shares of Nektar Therapeutics stock opened at $38.19 on Monday. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.93 and a quick ratio of 13.80. Nektar Therapeutics has a 52-week low of $33.50 and a 52-week high of $111.36. The stock has a market capitalization of $6.46 billion, a price-to-earnings ratio of -69.44 and a beta of 2.91.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.07. Nektar Therapeutics had a net margin of 59.71% and a return on equity of 79.66%. The firm had revenue of $27.80 million during the quarter, compared to analysts’ expectations of $26.08 million. During the same period in the previous year, the company earned $0.37 earnings per share. The firm’s quarterly revenue was down 81.8% on a year-over-year basis. As a group, research analysts predict that Nektar Therapeutics will post 3.66 EPS for the current year.

In other Nektar Therapeutics news, Director Dennis L. Winger sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 21st. The shares were sold at an average price of $59.96, for a total transaction of $1,798,800.00. Following the completion of the sale, the director now directly owns 57,750 shares of the company’s stock, valued at $3,462,690. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director R Scott Greer sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $67.39, for a total transaction of $673,900.00. Following the sale, the director now directly owns 140,333 shares of the company’s stock, valued at $9,457,040.87. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 46,750 shares of company stock valued at $2,855,830. 4.31% of the stock is owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in the business. Andra AP fonden increased its holdings in Nektar Therapeutics by 6.3% during the third quarter. Andra AP fonden now owns 16,800 shares of the biopharmaceutical company’s stock valued at $1,024,000 after buying an additional 1,000 shares during the last quarter. Cambridge Investment Research Advisors Inc. increased its holdings in Nektar Therapeutics by 27.0% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 4,784 shares of the biopharmaceutical company’s stock valued at $234,000 after buying an additional 1,018 shares during the last quarter. Flagship Harbor Advisors LLC increased its holdings in Nektar Therapeutics by 43.6% during the third quarter. Flagship Harbor Advisors LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 1,269 shares during the last quarter. United Services Automobile Association increased its holdings in Nektar Therapeutics by 2.6% during the second quarter. United Services Automobile Association now owns 50,077 shares of the biopharmaceutical company’s stock valued at $2,445,000 after buying an additional 1,281 shares during the last quarter. Finally, Securian Asset Management Inc increased its holdings in Nektar Therapeutics by 8.9% during the third quarter. Securian Asset Management Inc now owns 17,760 shares of the biopharmaceutical company’s stock valued at $1,083,000 after buying an additional 1,449 shares during the last quarter. 93.00% of the stock is owned by institutional investors and hedge funds.

About Nektar Therapeutics

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

See Also: Capital gains and your 401(k) or IRA

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply